Preclinical efficacy data support the therapeutic utility of peripherally restricted CB1 agonists in pain management, and antagonists in obesity, metabolic syndrome, and liver diseases. This evidence concerns the gene CNR1 and obesity due to melanocortin 4 receptor deficiency.